/
We intend to engage primarily in the development of regenerative medical applications which we intend to license, develop internally or acquire outright from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Ph…
The business is unprofitable at the operating level (-143.11% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 0.0%, essentially flat. This is a business that needs a catalyst.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$237K
Net Income (TTM)
-$716K
▼ -90.7% YoY
Op. Margin
-367.41%
▲ +33.3pp YoY
ROIC
-77.56%
▲ +17.7pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$477K
▲ +49.0% YoY
Net Debt
$817K
Cash & Equiv.
$271.00
5Y CAGR: +16.5%
Continue Research